Idorsia earns growth boost in Sfr330m deal
siro46 - stock.adobe.com
Investors poured into an accelerated trade in Swiss biopharmaceutical company Idorisia on Tuesday night, causing bookrunners to grow the deal by 1m shares. The success of the deal shows how highly investors value growth in the depressed economic environment of the Covid-19 pandemic.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts